Finerenone safety study for children with kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies how safely finerenone works over 18 months in children and young adults with chronic kidney disease who also take an ACE inhibitor or ARB. It aims to better understand long-term side effects when used together with standard kidney blood-pressure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 18 years old when you sign consent/assent
- Have chronic kidney disease and protein in the urine, and meet kidney filter levels (eGFR ≥30)
- Be taking an ACE inhibitor or ARB at the highest dose you can tolerate for at least 30 days
- Have potassium levels that are not too high (limits depend on age)
- Have already been in the earlier finerenone Phase 3 study (FIONA) and were not permanently stopped
- Not be planning kidney transplant during the study and not have certain blood-pressure or medical exclusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This observational study tracks how well finerenone (a kidney-protective medication) works in adults with type 2 diabetes and chronic kidney disease in Spain. Researchers will measure changes in kidney function and disease risk over time to better understand the medication's real-world benefits.
This study looks at how the medication finerenone works in everyday medical practice for people with type 2 diabetes and certain stages of chronic kidney disease. It aims to see how safe and effective the treatment is outside of a clinical trial setting.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This study is for people in South Korea who have chronic kidney disease and type 2 diabetes and are already taking or about to start the medicine finerenone (Kerendia). The goal is to see how well finerenone works in everyday medical care, outside of a strict research setting.
This study tests the long-term safety of the drug finerenone when taken alongside standard heart failure treatments in children and young adults with weakened heart pumping function (left ventricular systolic dysfunction). It includes both children already in a related study and new infants under 6 months old.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.